Dianthus Therapeutics

(NASDAQ) DNTH

Current Price$95.48

Market Cap$5.23B

Since IPO (2023)+770%

5 Year-39%

1 Year+443%

1 Month+3%

Dianthus Therapeutics Financials at a Glance

Market Cap

$5.23B

Revenue (TTM)

$1.34M

Net Income (TTM)

-$11.32M

EPS (TTM)

-$4.14

P/E Ratio

-23.12

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$95.48

Volume

314

Open

$96.76

Price

$95.48

Volume

314

Open

$96.76

Previous Close

$95.48

Daily Range

$92.67 - $96.92

52-Week Range

$17.77 - $97.38

Estimated Earnings Date

Aug 6, 2026

Dividend

$0.00

Beta (Volatility)

1.04 (Average)

Price

$95.48

Volume

314

Open

$96.76

Previous Close

$95.48

Daily Range

$92.67 - $96.92

52-Week Range

$17.77 - $97.38

Estimated Earnings Date

Aug 6, 2026

DNTH News

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Jonathan PoncianoMay 18, 2026

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Jonathan PoncianoMar 18, 2026

Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run

Sarah SidlowJan 7, 2026

Dianthus (DNTH) Q2 Loss Widens 80%

Motley Fool Markets TeamAug 7, 2025

DNTH: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dianthus Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Marino Garcia, MBA

Website

dianthustx.com

Headquarters

New York, NY 10036, US

DNTH Financials

Key Financial Metrics (TTM)

Gross Margin

94.31%

Operating Margin

-14318.04%

Net Income Margin

-847.53%

Return on Equity

-1.78%

Return on Capital

-35.96%

Return on Assets

-0.91%

Earnings Yield

-4.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.23B

Shares Outstanding

54.67M

Volume

314

Avg. Volume

904.99K

Financials (TTM)

Gross Profit

$1.26M

Operating Income

-$191.29M

EBITDA

-$10.86M

Operating Cash Flow

-$130.29M

Capital Expenditure

-$199.00K

Free Cash Flow

-$130.49M

Cash & ST Invst.

$1.11B

Total Debt

$1.36M

Dianthus Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$463.00K

-60.2%

Gross Profit

$387.00K

-66.7%

Gross Margin

83.59%

N/A

Market Cap

$5.23B

N/A

Market Cap/Employee

$56.85M

N/A

Employees

N/A

Net Income

-$40.83M

-38.4%

EBITDA

-$40.76M

-38.7%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$1.11B

+322.2%

Total Debt

$1.36M

-2.3%

Accounts Receivable

$1.23M

+23.0%

Inventory

$0.00

N/A

Long Term Debt

$965.00K

-17.5%

Short Term Debt

$399.00K

+76.5%

Return on Assets

-0.91%

N/A

Return on Invested Capital

-15.83%

N/A

Free Cash Flow

-$28.87M

-4.4%

Operating Cash Flow

-$28.86M

-4.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

ELVNEnliven Therapeutics, Inc.

ELVNEnliven Therapeutics, Inc.$50.85+1.54%

ANABAnaptysBio, Inc.

ANABAnaptysBio, Inc.$65.97+4.47%

ATAIAtai Beckley Inc.

ATAIAtai Beckley Inc.$5.36+1.32%

TSHATaysha Gene Therapies, Inc.

TSHATaysha Gene Therapies, Inc.$6.73+6.15%

IMTXImmatics N.V.

IMTXImmatics N.V.$9.56+0.42%

NKTRNektar Therapeutics

NKTRNektar Therapeutics$65.39+2.73%

TRMLTourmaline Bio, Inc.

TRMLTourmaline Bio, Inc.$47.98+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$195.03+0.01%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$164.24+0.07%

INTCIntel

INTCIntel$131.71+0.03%

TSLATesla

TSLATesla$411.94+0.08%

AMZNAmazon

AMZNAmazon$240.21+0.03%

AAPLApple

AAPLApple$281.64-0.01%

MSFTMicrosoft

MSFTMicrosoft$368.76-0.01%

Questions About DNTH

What is the current price of Dianthus Therapeutics?

Dianthus Therapeutics is trading at $95.48 per share.

What is the 52-week range for Dianthus Therapeutics?

Over the past 52 weeks, Dianthus Therapeutics has traded between $17.77 and $97.38.

How much debt does Dianthus Therapeutics have?

As of the most recent reporting period, Dianthus Therapeutics reported total debt of $1.36M.

How much cash does Dianthus Therapeutics have on hand?

Dianthus Therapeutics reported $627.67M in cash and cash equivalents in its most recent financial results.

What is Dianthus Therapeutics’s dividend yield?

Dianthus Therapeutics does not currently have a dividend yield.

Dianthus Therapeutics

Dianthus Therapeutics Financials at a Glance

DNTH News

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000

Dianthus Therapeutics CFO Sells $9.5 Million in Stock

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run

Dianthus (DNTH) Q2 Loss Widens 80%

DNTH: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Dianthus Therapeutics

DNTH Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Dianthus Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About DNTH

What is the current price of Dianthus Therapeutics?

What is the 52-week range for Dianthus Therapeutics?

How much debt does Dianthus Therapeutics have?

How much cash does Dianthus Therapeutics have on hand?

What is Dianthus Therapeutics’s dividend yield?

Premium Investing Services